Proposal for A-769662

Overview of Therapeutic Candidate:
A-769662 is a synthetic small‐molecule compound belonging to the thienopyridone family that was originally identified for its capacity to directly activate AMP‐activated protein kinase (AMPK), a central regulator of cellular energy homeostasis. Unlike traditional AMPK activators such as AICAR or metformin, which rely on indirect mechanisms such as the elevation of intracellular AMP levels or mitochondrial complex I inhibition, A-769662 binds directly to the carbohydrate‐binding module (CBM) on the β1 regulatory subunit of the AMPK heterotrimer. This binding occurs at what is known as the allosteric drug and metabolite-binding (ADaM) site, resulting in a conformational change that facilitates the kinase activity of the catalytic α subunit and simultaneously protects the key activating phosphorylation site, Thr172, from dephosphorylation by protein phosphatases (Kim et al., 2011; Treebak et al., 2009). Because of its synthetic origin and the ease with which its chemical structure can be modified to optimize pharmacokinetics and target engagement, A-769662 represents a promising candidate for repurposing in diseases characterized by energy deficits and mitochondrial dysfunction, such as Friedreich’s Ataxia (FRDA). As a representative of a class of compounds engineered to engage cellular energy sensors with high specificity, A-769662 has been leveraged in a variety of preclinical models of metabolic dysfunction, where its effects on lipid metabolism, mitochondrial respiration, and antioxidant defense have been documented (Vincent et al., 2015).

Therapeutic History:
The body of evidence accumulated to date on A-769662 is predominantly preclinical, with the compound being extensively studied in biochemical, cellular, and animal systems rather than in clinical or veterinary settings. In isolated cell systems and animal models, A-769662 has been used to probe the regulatory mechanisms of AMPK activation in tissues such as skeletal muscle, liver, and heart. For instance, in cardiomyocyte studies, A-769662 has been shown to increase AMPK phosphorylation and to elicit downstream phosphorylation events that include the modification of acetyl-CoA carboxylase (ACC), which is classically used as a readout of AMPK activation (Chen et al., 2014; Kim et al., 2011). Preclinical work in metabolic disease models has demonstrated that this compound improves mitochondrial respiratory capacity and spares reserve respiratory capacity—an indication that the compound can enhance cellular oxidative metabolism (Vincent et al., 2015). Despite the promising data from these studies, searches in established clinical trial databases using the terms “A-769662 OR AMPK activator AND Friedreich’s Ataxia” have yielded no results, suggesting that while A-769662 has been well studied in the context of metabolic syndrome, diabetes, ischemia–reperfusion injury, and other related conditions, it has not yet been investigated for either FRDA or similar mitochondrial pathologies in a clinical setting (ClinicalTrials.gov, n.d.). This historical record underscores both the promise and the translational gap for A-769662 as a candidate for FRDA, where mitochondrial dysfunction and energy deficits play a central role in disease pathogenesis (Vincent et al., 2015; Kim et al., 2011).

Mechanism of Action:
A-769662 exerts its biological activity through a well-defined molecular mechanism that centers on the direct activation of AMPK. AMPK is a heterotrimeric enzyme composed of an α catalytic subunit and regulatory β and γ subunits. While the γ subunit is responsible for sensing changes in the AMP:ATP ratio, A-769662 bypasses this regulatory mechanism by binding directly to the β1 subunit at its CBM, located at a site distinct from the nucleotide-binding region (Kim et al., 2011; Treebak et al., 2009). Binding of A-769662 induces an allosteric conformational change that not only enhances the intrinsic kinase activity of the α subunit but also stabilizes the phosphorylated state at Thr172, a modification essential for full AMPK activation. This stabilization is achieved by reducing the rate at which protein phosphatases dephosphorylate Thr172, thereby maintaining AMPK in an active state even under conditions where intracellular AMP levels may not be elevated (Kim et al., 2011; Treebak et al., 2009).

Once activated, AMPK phosphorylates a range of downstream substrates that orchestrate a cellular shift from energy-consuming anabolic processes to energy-producing catabolic pathways. One of the best-characterized targets is ACC. Phosphorylation of ACC results in its inhibition, which in turn lowers the levels of malonyl-CoA—a key inhibitor of fatty acid oxidation—and thereby promotes the oxidation of fatty acids to generate ATP (Vincent et al., 2015). In addition to this metabolic shift, AMPK activation has been shown to upregulate the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). PGC-1α is recognized as a master regulator of mitochondrial biogenesis; its activation leads to the induction of nuclear respiratory factors (NRF-1 and NRF-2) and mitochondrial transcription factor A (TFAM), which collectively drive mitochondrial DNA replication and the synthesis of new mitochondria (García-Giménez et al., 2011; Carvalho et al., 2024). In cellular models where mitochondrial DNA (mtDNA) is severely depleted, treatment with A-769662 has been observed to partially restore mtDNA levels and improve mitochondrial membrane potential, highlighting its potential role in ameliorating mitochondrial dysfunction (Carvalho et al., 2024).

It is also noteworthy that while A-769662 is primarily characterized by its direct activation of AMPK, several studies have noted secondary actions that may be AMPK-independent. For example, in some astrocytic models, A-769662 has been reported to increase intracellular calcium levels and promote extracellular ATP release, which are effects that are not strictly dependent on AMPK activation (Walker et al., 2017; Moore et al., 2020). However, these additional actions do not detract from its core mechanism, which remains a targeted and specific activation of energy homeostasis pathways via AMPK, thereby setting the stage for improvements in mitochondrial biogenesis and energy production (Kim et al., 2011; Vincent et al., 2015).

Expected Effect:
Friedreich’s Ataxia is a multisystem neurodegenerative disease characterized by frataxin deficiency that leads to substantial mitochondrial dysfunction, manifesting in impaired oxidative phosphorylation, decreased ATP production, and heightened oxidative stress. It is well established that one of the compensatory cellular responses to mitochondrial dysfunction is the activation of mitochondrial biogenesis pathways, in which AMPK and PGC-1α play critical roles. The central hypothesis for repurposing A-769662 in FRDA is that its direct activation of AMPK in patient-derived cardiomyocytes and potentially other affected cell types will upregulate PGC-1α and thereby stimulate mitochondrial biogenesis. This improvement in mitochondrial mass and function is expected to restore coupling efficiency between substrate oxidation and ATP synthesis, ultimately leading to enhanced ATP production and a recovery of cellular energy homeostasis.

In vitro, when using FRDA patient-derived cardiomyocytes—which are of particular relevance given the high incidence of cardiomyopathy in FRDA—the addition of A-769662 is anticipated to result in a rapid and robust phosphorylation of AMPK, as evidenced by increased Thr172 phosphorylation in these cells (Kim et al., 2011; Chen et al., 2014). This activation, in turn, is expected to upregulate concentrations of PGC-1α, leading to an increased transcription of mitochondrial genes including TFAM, and thereby facilitating mtDNA replication and mitochondrial biogenesis (García-Giménez et al., 2011; Carvalho et al., 2024).

Furthermore, enhanced mitochondrial biogenesis, as driven by the increased expression of PGC-1α and associated transcription factors, should result in measurable improvements in cellular bioenergetics. These improvements would include an elevation in the oxygen consumption rate (OCR) and an increase in the spare respiratory capacity (SRC) of the cardiomyocytes, thereby enhancing their ability to meet high energy demands during stress conditions (Vincent et al., 2015; Li et al., 2023). In addition, restoration of the mitochondrial membrane potential (MMP) and improvements in coupling efficiency between electron transport and ATP synthesis are anticipated. Such improvements would directly counteract the defects observed in FRDA, where impaired mitochondrial function leads to chronic energy deficits and increased oxidative stress—a cascade that further exacerbates neurodegeneration and cardiomyopathy associated with the disease (Carvalho et al., 2024).

It is also important to consider that cardiomyocytes express all the necessary components of the AMPK signaling pathway, including the catalytic α subunit along with the β1 and γ subunits, as well as downstream effectors such as PGC-1α, making them especially responsive to pharmacological modulation by compounds like A-769662 (Chen et al., 2014; Chung et al., 2021). Thus, the expected assay outcome in FRDA cardiomyocytes treated with A-769662 is an increase in AMPK phosphorylation, a subsequent upregulation of PGC-1α and mitochondrial biogenesis markers, and ultimately an improvement in overall ATP production and mitochondrial coupling efficiency—a constellation of effects that should ameliorate the energy crisis inherent in FRDA pathology (Li et al., 2023; García-Giménez et al., 2011).

Overall Evaluation:
A-769662 emerges as a compelling therapeutic candidate for repurposing in Friedreich’s Ataxia due to its direct and selective activation of AMPK, which underpins a cascade of metabolic effects that are highly relevant to the pathophysiology of FRDA. One of the principal strengths of A-769662 is its ability to bypass the need for elevated intracellular AMP levels—often a limiting factor in diseases characterized by mitochondrial dysfunction—by directly engaging the AMPK complex through binding to the β1 subunit. This mechanism confers a predictable and robust activation of AMPK, leading to the downstream upregulation of PGC-1α and subsequent mitochondrial biogenesis, a process that is particularly desirable in FRDA where mitochondrial deficits are a key driver of disease progression (Kim et al., 2011; Treebak et al., 2009; García-Giménez et al., 2011).

In preclinical models, A-769662 has consistently demonstrated the capacity to enhance mitochondrial function by increasing oxygen consumption, spare respiratory capacity, and improving mitochondrial membrane potential—all essential parameters for restoring ATP production (Vincent et al., 2015; Carvalho et al., 2024). These biochemical and physiological effects are supported by a solid mechanistic understanding; by preventing the dephosphorylation of Thr172 on the α subunit of AMPK, A-769662 not only ensures sustained kinase activity but also guarantees that the cascade leading to mitochondrial biogenesis is engaged even in the face of an energy deficit. This is particularly important in FRDA, where energy homeostasis is disrupted due to frataxin deficiency and subsequent mitochondrial impairment (Carvalho et al., 2024; Chen et al., 2014).

However, despite its attractive mechanism and robust preclinical profile in models of metabolic dysfunction and ischemia–reperfusion injury, A-769662 has yet to be evaluated specifically in Friedreich’s Ataxia. Searches in clinical trial repositories indicate that there are no studies directly testing A-769662 or other AMPK activators in FRDA, which identifies a clear gap in the translational research needed to assess its therapeutic potential in this context (ClinicalTrials.gov, n.d.). This lack of direct clinical data represents a weakness that must be addressed through targeted preclinical studies using FRDA-specific cellular models and eventually animal models that recapitulate the mitochondrial deficits associated with FRDA.

Another challenge involves the demonstration of tissue-specific efficacy. While A-769662 has been shown to be effective in cardiomyocytes and liver cells, its distribution and bioavailability in other affected tissues—such as skeletal muscle and the nervous system, which are also impacted in FRDA—are less certain. Achieving therapeutic levels in all relevant tissues will be critical, particularly since FRDA is a multisystem disorder characterized by both cardiac and neurological manifestations (Treebak et al., 2009; Kim et al., 2011). Moreover, some studies have noted additional effects of A-769662, such as alterations in intracellular calcium signaling and extracellular ATP release that occur independently of AMPK activation (Walker et al., 2017; Moore et al., 2020). While these off-target actions do not necessarily undermine its potential use in FRDA, they do highlight the need for a careful dissection of on-target versus off-target effects in relevant disease models to optimize dosing and minimize potential side effects.

Furthermore, the multifaceted pathology of Friedreich’s Ataxia—which encompasses not only mitochondrial dysfunction and energy deficits but also oxidative stress, iron accumulation, and neurodegeneration—suggests that A-769662 may need to be used in combination with other therapeutic modalities. For instance, while activation of the AMPK-PGC-1α pathway could restore mitochondrial biogenesis and improve ATP production, additional agents that target oxidative stress or iron dysregulation might be necessary to fully address the comprehensive pathology of FRDA (García-Giménez et al., 2011). In this regard, A-769662 could serve as a valuable component of a combination therapy strategy, where its ability to enhance mitochondrial function is complemented by other agents that mitigate complementary aspects of the disease process.

In summary, A-769662 presents a cautiously optimistic opportunity for repurposing in Friedreich’s Ataxia. Its direct, AMP-independent mechanism of action allows for robust, selective activation of AMPK in cardiomyocytes and potentially other affected cell types, leading to upregulation of PGC-1α, promotion of mitochondrial biogenesis, and restoration of cellular energy homeostasis. These effects are strongly supported by preclinical data from models of metabolic disease and mitochondrial dysfunction (Kim et al., 2011; Vincent et al., 2015; Carvalho et al., 2024). However, the absence of any direct clinical or FRDA-specific preclinical studies necessitates further rigorous investigation. Future research must focus on validating the molecular mechanism in FRDA patient-derived cell models, determining optimal dosing and tissue distribution, and exploring potential off-target effects to ensure safety and efficacy (ClinicalTrials.gov, n.d.; Kim et al., 2011; Treebak et al., 2009).

References:
Carvalho, G., Repolês, B., Nguyen, T. V. H., Forslund, J. M. E., Ranjbarian, F., Mendes, I. C., Falabella, M., Doimo, M., Wanrooij, S., Pitceathly, R. D. S., Hofer, A., & Wanrooij, P. H. (2024). The specific AMPK activator A-769662 ameliorates pathological phenotypes following mitochondrial DNA depletion. bioRxiv. https://doi.org/10.1101/2024.03.14.584413

Chen, S., Zhu, P., Guo, H.-M., Sancho Solis, R., Wang, Y., Ma, Y., Wang, J., Gao, J., Chen, J.-M., Ge, Y., Zhuang, J., & Li, J. (2014). Alpha1 catalytic subunit of AMPK modulates contractile function of cardiomyocytes through phosphorylation of troponin I. Life Sciences, 98(2), 75–82. https://doi.org/10.1016/j.lfs.2014.01.006

Chung, M.-Y., Choi, H.-K., & Hwang, J.-T. (2021). AMPK activity: A primary target for diabetes prevention with therapeutic phytochemicals. Nutrients, 13(11), Article 4050. https://doi.org/10.3390/nu13114050

ClinicalTrials.gov. (n.d.). Search for A-769662 OR AMPK activator AND Friedreich’s Ataxia. Retrieved from https://clinicaltrials.gov

García-Giménez, J. L., Gimeno, A., Gonzalez-Cabo, P., Dasí, F., Bolinches-Amorós, A., Mollá, B., Palau, F., & Pallardó, F. V. (2011). Differential expression of PGC-1α and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts. PLoS ONE, 6, e20666. https://doi.org/10.1371/journal.pone.0020666

Kim, A. S., Miller, E. J., Wright, T. M., Li, J., Qi, D., Atsina, K., Zaha, V., Sakamoto, K., & Young, L. H. (2011). A small molecule AMPK activator protects the heart against ischemia–reperfusion injury. Journal of Molecular and Cellular Cardiology, 51, 24–32. https://doi.org/10.1016/j.yjmcc.2011.03.003

Li, D., Armand, L. C., Sun, F., Hwang, H., Wolfson, D., Rampoldi, A., Liu, R., Forghani, P., Hu, X., Yu, W.-M., Qu, C.-K., Jones, D. P., Wu, R., Cho, H. C., Maxwell, J. T., & Xu, C. (2023). AMPK activator-treated human cardiac spheres enhance maturation and enable pathological modeling. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-023-03554-7

Moore, T., Yanes, R. E., Calton, M. A., Vollrath, D., Enns, G. M., & Cowan, T. M. (2020). AMP-independent activator of AMPK for treatment of mitochondrial disorders. PLOS ONE, 15, Article e0240517. https://doi.org/10.1371/journal.pone.0240517

Treebak, J. T., Birk, J. B., Hansen, B. F., Olsen, G. S., & Wojtaszewski, J. F. P. (2009). A-769662 activates AMPK β1-containing complexes but induces glucose uptake through a PI3-kinase-dependent pathway in mouse skeletal muscle. American Journal of Physiology-Cell Physiology, 297(4), C1041–C1052. https://doi.org/10.1152/ajpcell.00051.2009

Vincent, E., Coelho, P., Blagih, J., Griss, T., Viollet, B., & Jones, R. G. (2015). Differential effects of AMPK agonists on cell growth and metabolism. Oncogene, 34, 3627–3639. https://doi.org/10.1038/onc.2014.301

Walker, J. M. V., Robb, J. L., Cruz, A. M., Malhi, A., Weightman Potter, P. G., Ashford, M. L. J., McCrimmon, R. J., Ellacott, K. L. J., & Beall, C. (2017). AMP-activated protein kinase (AMPK) activator A-769662 increases intracellular calcium and ATP release from astrocytes in an AMPK-independent manner. Diabetes, 19, 1005–997. https://doi.org/10.1111/dom.12912
